JP Morgan Chase’s OptiNose OPTN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-431
Closed -$3.95K 7494
2025
Q1
$3.95K Sell
431
-18
-4% -$113 ﹤0.01% 6463
2024
Q4
$3K Sell
449
-19
-4% -$167 ﹤0.01% 6585
2024
Q3
$4.7K Sell
468
-62
-12% -$904 ﹤0.01% 6499
2024
Q2
$8.26K Sell
530
-7,960
-94% -$133K ﹤0.01% 6292
2024
Q1
$186K Buy
8,490
+5,070
+148% +$113K ﹤0.01% 5391
2023
Q4
$66.2K Sell
3,420
-1,353
-28% -$24.7K ﹤0.01% 5905
2023
Q3
$88.1K Buy
4,773
+442
+10% +$7.96K ﹤0.01% 5559
2023
Q2
$79.9K Buy
4,331
+2,973
+219% +$70.3K ﹤0.01% 5559
2023
Q1
$39K Buy
1,358
+304
+29% +$8.09K ﹤0.01% 5796
2022
Q4
$29K Buy
1,054
+667
+172% +$25.3K ﹤0.01% 5767
2022
Q3
$21K Buy
387
+142
+58% +$7.79K ﹤0.01% 5792
2022
Q2
$13K Sell
245
-407
-62% -$15K ﹤0.01% 5987
2022
Q1
$24K Buy
652
+165
+34% +$5.89K ﹤0.01% 6034
2021
Q4
$12K Sell
487
-1,226
-72% -$41K ﹤0.01% 6305
2021
Q3
$77K Sell
1,713
-3,710
-68% -$156K ﹤0.01% 5692
2021
Q2
$253K Sell
5,423
-2,617
-33% -$134K ﹤0.01% 5111
2021
Q1
$445K Sell
8,040
-1,159
-13% -$70.5K ﹤0.01% 4746
2020
Q4
$571K Buy
9,199
+8,330
+959% +$510K ﹤0.01% 4291
2020
Q3
$50K Sell
869
-569
-40% -$42.1K ﹤0.01% 4933
2020
Q2
$161K Sell
1,438
-194,711
-99% -$13.9M ﹤0.01% 4363
2020
Q1
$13.2M Buy
196,149
+1,830
+0.9% +$184K ﹤0.01% 1518
2019
Q4
$26.9M Buy
194,319
+4,261
+2% +$553K 0.01% 1360
2019
Q3
$20M Buy
190,058
+12,210
+7% +$1.22M ﹤0.01% 1582
2019
Q2
$17.1M Buy
177,848
+10,917
+7% +$1.44M ﹤0.01% 1687
2019
Q1
$25.8M Buy
166,931
+12,478
+8% +$1.45M 0.01% 1367
2018
Q4
$14.4M Buy
154,453
+29,504
+24% +$4.21M ﹤0.01% 1737
2018
Q3
$23.3M Buy
124,949
+35,100
+39% +$10M ﹤0.01% 1548
2018
Q2
$37.7M Buy
89,849
+89,776
+122,981% +$30.3M 0.01% 1142
2018
Q1
$22K Sell
73
-5
-6% -$1.39K ﹤0.01% 5063
2017
Q4
$22K Buy
+78
New +$21.9K ﹤0.01% 5146

JP Morgan Chase's OPTN Position: Q2 2025 in Review

JP Morgan Chase sold out of OptiNose (OPTN) in Q2 2025, closing a stake of 431 shares — an estimated $3.95K sold.

JP Morgan Chase first reported a position in OPTN in Q4 2017 and held it in 30 quarters. The position peaked at $37.7M in Q2 2018. 0 funds tracked by Wall St. Rank hold OPTN as of Q2 2025.

  • JP Morgan Chase reported no remaining OptiNose position as of Q2 2025 after selling out during the quarter.
  • JP Morgan Chase sold 431 OptiNose shares in Q2 2025, an estimated $3.95K.
  • JP Morgan Chase first reported a position in OptiNose in Q4 2017 and held it in 30 quarters.
  • JP Morgan Chase's OptiNose position peaked at $37.7M in Q2 2018.
  • 0 funds tracked by Wall St. Rank held OptiNose as of Q2 2025.

Based on JP Morgan Chase's 13F filing for Q2 2025, filed 12 Aug 2025.